Pharming Group (NASDAQ:PHAR) Short Interest Update

Pharming Group (NASDAQ:PHAR) saw a large decrease in short interest during the month of June. As of June 30th, there was short interest totalling 2,900 shares, a decrease of 63.8% from the June 15th total of 8,000 shares. Based on an average trading volume of 4,900 shares, the short-interest ratio is presently 0.6 days.

Pharming Group Trading Up 4.6 %

PHAR traded up $0.38 during trading on Friday, reaching $8.76. 600 shares of the company’s stock were exchanged, compared to its average volume of 3,736. Pharming Group has a one year low of $6.97 and a one year high of $16.71. The firm has a fifty day moving average price of $8.73 and a two-hundred day moving average price of $10.42. The stock has a market capitalization of $589.93 million, a PE ratio of -54.75 and a beta of 0.15.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.20). The business had revenue of $55.59 million during the quarter, compared to the consensus estimate of $68.43 million. Pharming Group had a negative return on equity of 4.61% and a negative net margin of 4.01%. Sell-side analysts expect that Pharming Group will post -0.03 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research note on Friday, May 31st.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its position in shares of Pharming Group (NASDAQ:PHAR) by 32.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent SEC filing. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.